Astellas Pharma Receivables

Astellas Pharma (ALPMY) currently reports a receivables of $840B as of June 2026. That compares with $670B in the prior-year period — up 25.5% year over year. Use the charts on this page to explore Astellas Pharma's receivables history and peer comparisons.

Astellas Pharma's receivables increased from $670B to $840B — a 25.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Astellas Pharma reported $840B in receivables as of June 2026. That compares with $670B in the prior-year period — up 25.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $840B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Astellas Pharma, and consider following ALPMY for alerts when major investors trade the stock.

Astellas Pharma is classified in the Healthcare sector. On receivables, it currently shows $840B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALPMY with unrelated industries.